8-K: AVITA Medical Amends Loan, Reports Q3 Revenue Decline

AVITA Medical reported a 13% decrease in Q3 2025 commercial revenue to $17.1 million, revised its full-year outlook, and amended its credit agreement with OrbiMed.

Summary

• Commercial revenue for Q3 2025 was $17.1 million, a 13% decrease compared to $19.5 million in Q3 2024.
• The company's full-year 2025 revenue outlook was revised downwards to $70 million to $74 million, from prior guidance of $76 million to $81 million.
• Net loss improved to $13.2 million, or $0.46 per basic and diluted share, compared to a net loss of $16.2 million, or $0.62 per share, in Q3 2024.
• Operating expenses decreased by 24%, or $7.2 million, to $23.0 million in Q3 2025, compared with $30.2 million in Q3 2024.
• Net use of cash improved to $6.2 million in Q3 2025, compared to $10.1 million in Q2 2025.
• Cash, cash equivalents, and marketable securities totaled $23.3 million as of September 30, 2025.
• AVITA Medical entered into a Sixth Amendment to its Credit Agreement with OrbiMed Advisors, LLC affiliates, modifying the trailing 12-month revenue covenant for the quarter ending December 31, 2025, to $70.0 million (down from $77.0 million).
• The Sixth Amendment also waived a requirement that the company's Quarterly Report on Form 10-Q not contain any qualification or statement of a going concern or similar nature for the quarter ending September 30, 2025.
• In consideration for the amended covenant and waiver, the company agreed to add $500,000 to the principal balance of the Credit Agreement, with interest payable from November 1, 2025.
• RECELL GO received CE Mark approval under the EU Medical Device Regulation, enabling European launch beginning with Germany, Italy, and the United Kingdom.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to a significant decline in commercial revenue, a downward revision of full-year guidance, and the necessity of amending credit covenants and obtaining a 'going concern' waiver. While cost reductions and new market approvals are positive, they are overshadowed by the financial distress signals.

Positives

• Net loss improved to $13.2 million in Q3 2025 from $16.2 million in Q3 2024.
• Operating expenses decreased by 24% ($7.2 million) to $23.0 million, reflecting disciplined cost-management and sustained reductions from a Q2 commercial field transformation.
• Net use of cash improved significantly to $6.2 million in Q3 2025, compared to $10.1 million in Q2 2025, indicating improving cash efficiency.
• RECELL GO received CE Mark approval under the EU Medical Device Regulation, enabling commercialization in Europe.
• Clinical data from over 8,000 patients reinforced RECELL's ability to achieve wound closure with less donor skin, faster healing, and reduced patient burden.
• U.S. registry data demonstrated a 36% reduction in length of hospital stay and approximately $42,000 in per-patient cost savings for RECELL compared to traditional split thickness skin grafts in adult patients with deep partial thickness burns.
• Reimbursement clarity for RECELL has largely been restored, with all seven Medicare Administrative Contractors (MACs) publishing or confirming payment rates under new Category I CPT codes.

Negatives

• Commercial revenue decreased by 13% to $17.1 million in Q3 2025 compared to the same period in 2024.
• The full-year 2025 revenue outlook was revised downwards to $70 million to $74 million, from previous guidance of $76 million to $81 million.
• The company required a waiver for the Q3 2025 revenue covenant and an amendment to lower the Q4 2025 trailing 12-month revenue covenant from $77.0 million to $70.0 million.
• An additional $500,000 was added to the principal balance of the Credit Agreement as consideration for the covenant amendment and waiver.
• The company required a waiver for a 'going concern' qualification or similar statement in its Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.
• Gross profit margin decreased to 81.3% in Q3 2025 from 83.7% in Q3 2024, primarily due to product mix with lower margin products like Cohealyx and PermeaDerm.

Risks

• The company's ability to achieve anticipated benefits from regulatory approvals of its products.
• Physician acceptance, endorsement, and use of products, including the impact of government reimbursement payment rates.
• The effect of regulatory actions on the business.
• Potential product liability claims.
• Risks associated with international operations and expansion.
• Other business effects, including the impact of industry, economic, or political conditions outside of the company's control.
• The need for a waiver regarding a 'going concern' statement in the Q3 2025 10-Q indicates significant financial uncertainty.

Future Outlook

The company now expects full-year 2025 revenue to be in the range of $70 million to $74 million, a reduction from prior guidance. Management is evaluating capital funding options and expects to provide an update on capital and growth plans, along with 2026 revenue and financial guidance, in early Q1 2026. The company remains focused on disciplined cash management, sharpening execution, and accelerating commercial momentum across its core U.S. burn and trauma center opportunity.

Management Comments

• Cary Vance, Interim Chief Executive Officer, stated: "My focus will be on execution – building the use of RECELL, driving consistent and predictable utilization of our products across burn, trauma, and surgical settings, and completing a full and successful transition of our commercial organization."
• Vance also noted: "Our quarterly results reflected the impact of delayed clinician reimbursement transitions for RECELL, the pace of hospital VAC reviews for Cohealyx – which naturally take time – and the evolution of our commercial organization. As these factors normalize, we are well positioned to strengthen execution and advance our mission to make AVITA’s products the standard in acute wound care."
• David O'Toole, Chief Financial Officer, commented: "We continue to execute on our disciplined cost-management strategy while aligning spending with growth priorities, achieving a 24% year-over-year decrease in total operating expenses, representing a reduction of $7.2 million to $23.0 million this quarter."
• O'Toole added: "Importantly, use of cash improved to $6.2 million in the third quarter compared to $10.1 million in the prior quarter, highlighting our improving cash efficiency. We also reached an agreement with OrbiMed to waive the Q3 revenue covenant at no fee and to reset the revenue covenant for the fourth quarter."
• O'Toole further stated: "In parallel, we are evaluating capital funding options and expect to provide an update, together with 2026 revenue and financial guidance in early Q1 2026."

Industry Context

AVITA Medical operates in the therapeutic acute wound care market, focusing on burn and trauma treatment. The company's RECELL System is positioned as a leader in this space, with new clinical data reinforcing its efficacy. The CE Mark approval for RECELL GO expands the company's international presence, particularly in key European markets. The restoration of reimbursement clarity for RECELL under new Category I CPT codes by Medicare Administrative Contractors is a significant development for clinician confidence and procedure volumes within the U.S. market, which is estimated at roughly $1.3 billion for the company's target segment.

Comparison to Industry Standards

• RECELL's clinical data from a global systematic review of over 8,000 patients confirmed its ability to achieve wound closure with less donor skin, faster healing, and reduced patient burden compared to traditional methods.
• U.S. registry data demonstrated a 36% reduction in length of hospital stay and approximately $42,000 in per-patient cost savings for RECELL compared to traditional split thickness skin grafts in adult patients with deep partial thickness (second degree) burns affecting up to 30% total body surface area.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into a Sixth Amendment to its Credit Agreement with affiliates of OrbiMed Advisors, LLC (Lenders).
• In consideration for the Sixth Amendment, the company agreed to add $500,000 to the principal balance of the Credit Agreement with OrbiMed.
• In August, the company issued 400,000 shares of common stock to OrbiMed for a fifth amendment to its credit agreement, resulting in a non-cash charge of $2.2 million.

Stakeholder Impact

• Shareholders: Negative impact from declining revenue, lowered guidance, potential dilution from future capital raises, and the 'going concern' waiver, which signals financial instability.
• Lenders (OrbiMed): Benefited from an additional $500,000 added to the principal balance and 400,000 shares of common stock for covenant relief and waivers, indicating increased leverage over the company.
• Customers/Clinicians: Restoration of reimbursement clarity for RECELL is positive, potentially increasing confidence and procedure volumes.
• Employees: Operating expense reductions, including lower salaries, benefits, and stock-based compensation, suggest potential impacts on personnel following the Q2 commercial field transformation.

Next Steps

• Launch RECELL GO in Europe, starting with Germany, Italy, and the United Kingdom.
• Provide an update on capital and growth plans in early Q1 2026.
• Provide 2026 revenue and financial guidance in early Q1 2026.
• Continue disciplined cash management, sharpen execution, and accelerate commercial momentum across core U.S. burn and trauma centers.

Key Dates

Recommendation

The company's Q3 2025 results show a significant 13% year-over-year decline in commercial revenue, coupled with a substantial downward revision of its full-year 2025 revenue guidance. The most concerning factors are the necessity of obtaining a waiver for a 'going concern' statement in its 10-Q and the payment of $500,000 to lenders to amend a revenue covenant. These actions strongly indicate severe financial distress and potential liquidity challenges. While cost reductions and improved cash burn are positive operational steps, they are insufficient to offset the fundamental revenue weakness and the gravity of the financial covenant breaches and waivers. The stock presents a high-risk profile, and a strong sell recommendation is warranted given the clear signals of financial instability and uncertainty.

Keywords

AVITA Medical, RCEL, AVH, Q3 2025, financial results, revenue, net loss, operating expenses, cash flow, credit agreement, OrbiMed, revenue covenant, going concern, RECELL System, RECELL GO, wound care, burn treatment, trauma, CPT codes, reimbursement, medical device, capital raise